TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05525715
Drug: 20mg QY201 tablets，BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg QY201 tablets，BID
Study: NCT05525715
Drug: QY201 placebo，BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: QY201placebo，BID
Study: NCT04728581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a gelatinous capsule without an active ingredient
Study: NCT05195827
Drug: PRM-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive
Study: NCT05013567
Drug: Ibuprofen gel
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen gel 5% topically four times a day
Study: NCT05733533
Drug: Matching placebo to HRS-2261
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to HRS-2261, oral, BID
Study: NCT05620355
Drug: BG2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG2109 100mg film coated tablet for oral administration once daily.
Study: NCT05620355
Drug: Placebo for BG2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for BG2109 100mg tablet for oral administration once daily.
Study: NCT05620355
Drug: Placebo for add-back therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for add-back therapy tablet for oral administration once daily.
Study: NCT06108791
Drug: FIO2=0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air
Study: NCT06108791
Drug: FIO2=0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air
Study: NCT04862845
Drug: sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
Study: NCT01970111
Drug: KPS-0373, High dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01970111
Drug: KPS-0373, Low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05187637
Drug: intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of intravenous iron carboxymaltose calculated according to ganzoni's formula. If after thirty days of the first dose, a second dose of 500mg will be administered if the patient continues to meet the inclusion criteria.
Study: NCT05508594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal
Study: NCT05508594
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal
Study: NCT04806945
Drug: Placebo to HLX10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05697003
Drug: ADVAIR DISKUS 100/50
Normalized name: Advair Diskus 100/50 Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations in one study period
Study: NCT04867603
Drug: [Ga-68]PSMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.
Study: NCT05511051
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC
Study: NCT05151146
Drug: ANJ900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin hydrochloride delayed-release tablets
Study: NCT05982392
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550mg will be given 60 minutes before start of procedure.
Study: NCT05982392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given 60 minutes before start of procedure.
Study: NCT05390944
Drug: IMP4297(20mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
Study: NCT05390944
Drug: IMP4297(10mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
Study: NCT06427031
Drug: TJO-083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
Study: NCT05241067
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Dose: equal volume saline) + Standard of care
Study: NCT05549206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution
Study: NCT05312398
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter
Study: NCT05312398
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line
Study: NCT06149507
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribe the drug to the child
Study: NCT06149507
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prescribe the drug to the child
Study: NCT05811975
Drug: KSX01-TCRT injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: individualization TCR-T cell injection
Study: NCT05706402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
Study: NCT06543290
Drug: Azithromycin Pill
Normalized name: azithromycin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm
Study: NCT05587400
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitric oxide inhalation
Study: NCT05689931
Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Study: NCT05416320
Drug: Subject's already prescribed drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
Study: NCT06107673
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI: Take according to the instructions provided.
Study: NCT06107673
Drug: Cyclophosphamide injection
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study: NCT05360576
Drug: LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)
Normalized name: ethinyl estradiol / etonogestrel Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: To prevent pregnancy
Study: NCT05360576
Drug: NuvaRing Vaginal Ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: To prevent pregnancy
Study: NCT06274437
Drug: BND-35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT06377085
Drug: Placebo for the AZA 10mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group for the 10mg/m\^2, one-time subcutaneous injection without the active treatment.
Study: NCT06377085
Drug: Placebo for the AZA 20mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group for the 20mg/m\^2, one-time subcutaneous injection without the active treatment.
Study: NCT06377085
Drug: Placebo for the AZA 35mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group for the 35mg/m\^2, one-time subcutaneous injection without the active treatment.
Study: NCT06377085
Drug: Placebo for the AZA 75mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group for the 75mg/m\^2, one-time subcutaneous injection without the active treatment.
Study: NCT05163535
Drug: VM-1500A-LAI
Normalized name: laidlomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form
Study: NCT04983498
Drug: Lactated Ringers, Intravenous
Normalized name: Lactated Ringers, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
Study: NCT06478940
Drug: 3 mixtatin pulpotomy
Normalized name: HISTATIN 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
Study: NCT06478940
Drug: MTA pulpotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pulp treatment with applying MTA
Study: NCT04540406
Drug: NBT-NM108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
Study: NCT04972175
Drug: 50-Hour Intervention - BC LisPram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous-delivery of BC LisPram using pump therapy.
Study: NCT06305546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
Study: NCT00320580
Drug: norelgestromin/ethinyl estradiol
Normalized name: norelgestromin/ethinyl estradiol 150 mcg-35 mcg/24 hour TRANSDERM PATCH, TRANSDERMAL WEEKLY
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04933058
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain management
Study: NCT04933058
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pain management
Study: NCT05248022
Drug: Programmed Cell Death Protein 1 Inhibitor
Normalized name: Programmed cell death protein 1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
Study: NCT06033521
Drug: Menopausal hormone therapy Intervention Type: Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
Study: NCT05860400
Drug: Secondary prevention for atherosclerotic coronary artery disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
Study: NCT05860400
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids and/or immunosuppressive agents
Study: NCT05860400
Drug: Supportive therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
Study: NCT05954988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04745988
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
Study: NCT04630886
Drug: Lidocaine Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
Study: NCT05397405
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
Study: NCT05896124
Drug: 2mg CS0159
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral QD
Study: NCT05896124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral QD
Study: NCT06334315
Drug: Desogestrel / Ethinyl Estradiol Pill
Normalized name: desogestrel / ethinyl estradiol Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pill packs containing 21 active pills and 7 placebo pills
Study: NCT05199272
Drug: 23ME-00610
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23ME-00610 given by IV infusion
Study: NCT05718518
Drug: ASC11 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)
Study: NCT05718518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 and 2: Subjects will be randomized to receive placebo.
Study: NCT05718518
Drug: RTV tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)
Study: NCT05460000
Drug: 3 cycles chemotherapy instead of 6 cycles chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
Study: NCT05460000
Drug: 6 cycles chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy as comparator
Study: NCT05715346
Drug: LEV102 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline ophthalmic gel
Study: NCT05715346
Drug: LEV102 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline ophthalmic gel
Study: NCT05715346
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ophthalmic gel
Study: NCT02545127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Study: NCT05343507
Drug: Ketalar 50 MG/ML Injectable Solution
Normalized name: Ketalar 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution (other info already provided)
Study: NCT05343507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Solution
Study: NCT05564923
Drug: there is no intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: there is no intervention
Study: NCT05040464
Drug: AZA capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral AZA capsules at a daily dose of 2.5 mg per kilogram,
Study: NCT05575427
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive minocycline oral between 7-28 days
Study: NCT05575427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule without active compound
Study: NCT05244577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo,Ondansetron,Dexamethasone,Fosaprepitant
Study: NCT01341548
Drug: Civamide nasal solution 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ug/dose, BID for 7 days 0.1 ml to each nostril
Study: NCT05946772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
Study: NCT05333744
Drug: Recombinant Human TPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
Study: NCT06202989
Drug: Multiprofen-CC™ plus standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
Study: NCT04819620
Drug: PN-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Drug
Study: NCT04819620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT06090721
Drug: DMT310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Powder
Study: NCT06090721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Powder
Study: NCT05829317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl
Study: NCT04771871
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
Study: NCT05529173
Drug: 0.9% NaCl Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal swab stick application of 0.9% NaCl Solution prior to surgery
Study: NCT06150014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
Study: NCT06150014
Drug: TQA3605 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQA3605 inhibits viral replication.
Study: NCT06232421
Drug: Foscelantan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus
Study: NCT05013229
Drug: IcoSema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
Study: NCT06054464
Drug: PC14586
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
Study: NCT04667429
Drug: HEC83518
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC83518 will be taken orally before sleep for 15 days
Study: NCT04667429
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered before sleep for 15 days.
Study: NCT05800847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
Study: NCT05095337
Drug: [14C]SHR1459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single dose of orally \[14C\]SHR1459 on Day 1.
Study: NCT05177263
Drug: 10% Oral Dextrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Oral Dextrose Solution
Study: NCT05177263
Drug: 20% Oral Dextrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Oral Dextrose Solution
Study: NCT05177263
Drug: 30% Oral Dextrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% Oral Dextrose Solution
Study: NCT03724227
Drug: ACE-011
Normalized name: dibucaine 0.011 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-011 will be administered subcutaneous injection
Study: NCT04776252
Drug: MK-8591A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
Study: NCT05516966
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated SC
Study: NCT05516966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated SC
Study: NCT06260748
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg capsules
Study: NCT06260748
Drug: Chenodeoxycholic acid Placebo
Normalized name: chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT05107934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride solution for Injection
Study: NCT04895280
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
Study: NCT06355687
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.